公开(公告)号：US20030185760A1

公开(公告)日：2003-10-02

申请号：US10153395

申请日：2002-05-21

发明人： Gregory Lanza ,  Samuel A. Wickline

IPC分类号： A61K049/00

CPC分类号： B82Y5/00 ,  A61K49/1881

摘要： An improved contrast agent for magnetic resonance imaging comprises particles to each of which is coupled a multiplicity of chelating agents containing paramagnetic ions. In the improved agent, the position of the ion is offset from the surface of the particle so as to improve the relaxivity imparted by the contrast agent.

摘要翻译： 用于磁共振成像的改进的造影剂包括颗粒，其中每个颗粒与多个含有顺磁离子的螯合剂偶联。 在改进剂中，离子的位置偏离粒子的表面，以提高造影剂赋予的松弛度。

公开(公告)号：US5114703A

公开(公告)日：1992-05-19

申请号：US530034

申请日：1990-05-29

申请人： Gerald L. Wolf ,  David M. Long

发明人： Gerald L. Wolf ,  David M. Long

IPC分类号： A61K49/00 ,  A61K49/04 ,  A61K49/18

CPC分类号： B82Y5/00 ,  A61K49/0471 ,  A61K49/128 ,  A61K49/1806 ,  A61K49/1818 ,  A61K49/1863 ,  A61K49/1866 ,  A61K49/1881 ,  Y10S514/832 ,  Y10S514/937 ,  Y10S514/938 ,  Y10S514/941 ,  Y10S514/943 ,  Y10T436/24

摘要： Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

摘要翻译： 注射造影剂对于淋巴造影具有极大的临床重要性，其特征在于约5或10nm至约500或900nm之间的非水溶性颗粒尺寸，其经皮给药具有选择性分布于淋巴结并且可以以毫米分辨率成像。 还公开了使用这些造影剂进行经皮淋巴造影的方法。

公开(公告)号：US12083191B2

公开(公告)日：2024-09-10

申请号：US16573570

申请日：2019-09-17

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： James Basilion ,  Kirti Dhingra ,  Thomas J. Meade ,  Sarah Grace Kamper

IPC分类号： A61K49/18 ,  A61K49/00 ,  A61K49/08 ,  A61K49/14

CPC分类号： A61K49/1881 ,  A61K49/0017 ,  A61K49/085 ,  A61K49/14

摘要： A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

公开(公告)号：US20230405154A1

公开(公告)日：2023-12-21

申请号：US18253586

申请日：2021-11-19

申请人： NH THERAGUIX ,  UNIVERSITE CLAUDE BERNARD LYON 1 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

发明人： Olivier TILLEMENT ,  François LUX ,  Fabien ROSSETTI ,  Paul ROCCHI ,  Tristan DOUSSINEAU

IPC分类号： A61K49/18 ,  A61K51/12

CPC分类号： A61K49/1881 ,  A61K51/1244 ,  B82Y5/00

摘要： The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

公开(公告)号：US09938526B2

公开(公告)日：2018-04-10

申请号：US15162872

申请日：2016-05-24

申请人： Juan Sanchez-Ramos ,  Vasyl Sava ,  Shijie Song ,  Shyam S. Mohapatra ,  Subhra Mohapatra

发明人： Juan Sanchez-Ramos ,  Vasyl Sava ,  Shijie Song ,  Shyam S. Mohapatra ,  Subhra Mohapatra

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K9/00 ,  A61K9/107 ,  A61K9/16 ,  A61K9/50 ,  A61K49/18 ,  C12N15/88 ,  C12N15/89 ,  A61K9/51 ,  A61K31/7088 ,  A61K47/54 ,  A61K47/69 ,  A61K48/00

CPC分类号： C12N15/113 ,  A61K9/0043 ,  A61K9/1075 ,  A61K9/1611 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/50 ,  A61K9/501 ,  A61K9/5115 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/541 ,  A61K47/547 ,  A61K47/6939 ,  A61K48/00 ,  A61K49/1881 ,  C12N15/88 ,  C12N15/895 ,  C12N2310/14 ,  C12N2320/32

摘要： The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins. Although this receptor has particular affinity for manganese, it is contemplated that other divalent ions, including magnesium, calcium, and the like may also be bound to such receptors leading to transport of the nanoparticles into the intracellular cytoplasm. Nanoparticles have been developed, therefore, as vehicles for parenteral delivery of genes, proteins and drugs. The present disclosure encompasses embodiments of nanoparticle-based compositions and methods for the use thereof for the delivery of genes, oligonucleotides, including but not limited to small interfering RNA, and other small molecule drugs, into the brain by nasal insufflation.

公开(公告)号：US09675714B1

公开(公告)日：2017-06-13

申请号：US14186845

申请日：2014-02-21

申请人： Subhra Mohapatra ,  Chunyan Wang

发明人： Subhra Mohapatra ,  Chunyan Wang

IPC分类号： A61K51/00 ,  A61M36/14 ,  A61K49/18 ,  A61K31/704 ,  A61K48/00 ,  A61K49/00

CPC分类号： A61K49/1881 ,  A61K31/704 ,  A61K47/6923 ,  A61K48/0041 ,  B82Y5/00

摘要： Disclosed herein are theranostic nanoparticles configured for simultaneous delivery of a diagnostic moiety, drug moiety, and a gene therapy moiety. In one embodiment, the theranostic nanoparticles contain a super paramagnetic iron oxide chemotherapeutic loaded on a chitosan functionalized 2D graphene sheet with a gene therapy moiety attached to the surface of the chitosan functionalized 2D graphene sheet. Also disclosed are methods for making and administering theranositic nanoparticles configured for simultaneous delivery of a diagnostic moiety, drug moiety, and a gene therapy moiety.

公开(公告)号：US09579404B2

公开(公告)日：2017-02-28

申请号：US14492749

申请日：2014-09-22

申请人： New York University

发明人： Marc Anton Walters

IPC分类号： A61K49/00 ,  A61K49/18 ,  A61K49/10 ,  A61K49/12 ,  A61K9/51 ,  C07D257/02 ,  C07F5/00

CPC分类号： A61K49/106 ,  A61K9/5153 ,  A61K9/5176 ,  A61K49/108 ,  A61K49/124 ,  A61K49/1809 ,  A61K49/1818 ,  A61K49/1881 ,  C07D257/02 ,  C07F5/003

摘要： The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.

摘要翻译： 本发明涉及DOTA衍生物化合物，镧系元素-DTA衍生物分子复合物和镧系元素复合物包封的固体脂质颗粒或胶囊的组合物，以及制备和使用该组合物的方法。 固体脂质颗粒或胶囊含有由交联的DOTA衍生物化合物或交联的镧系元素-DTA衍生物复合物形成的超支化聚合物壳稳定的胶束核。 这些固体脂质颗粒或胶囊可用于各种应用，例如造影剂或药物递送载体。

公开(公告)号：US20160038618A1

公开(公告)日：2016-02-11

申请号：US14823891

申请日：2015-08-11

申请人： William Marsh Rice University

发明人： Nancy J. Halas ,  Ciceron Ayala-Orozco ,  Sandra Bishnoi

IPC分类号： A61K49/18

CPC分类号： A61K49/1881

摘要： A magnetic resonance imaging enhancement agent includes a plurality of particles. Each particle including a metal core; a dielectric shell disposed on the metal core including water and at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.

摘要翻译： 磁共振成像增强剂包括多个颗粒。 每个颗粒包括金属芯; 布置在所述金属芯上的介电壳，包括水和至少一个MRI造影剂; 以及设置在电介质壳的外表面上的金属壳，其封装介电壳。

公开(公告)号：US09139611B2

公开(公告)日：2015-09-22

申请号：US12373176

申请日：2007-07-13

申请人： Richard Alan Johnson ,  John Rodney Woodrow

发明人： Richard Alan Johnson ,  John Rodney Woodrow

IPC分类号： C07K17/00 ,  C07K1/02 ,  A61K9/16 ,  A61K9/51 ,  A61K47/48 ,  A61K49/04 ,  A61K49/08 ,  A61K49/14 ,  A61K49/18 ,  A61K51/08 ,  A61K51/12 ,  B82Y5/00 ,  C07K1/08 ,  C07K1/10

CPC分类号： C07K1/02 ,  A61K9/1658 ,  A61K9/5169 ,  A61K47/64 ,  A61K47/643 ,  A61K47/6435 ,  A61K47/644 ,  A61K47/6929 ,  A61K49/0485 ,  A61K49/085 ,  A61K49/143 ,  A61K49/1881 ,  A61K51/081 ,  A61K51/1255 ,  B82Y5/00 ,  C07K1/08 ,  C07K1/10

摘要： Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL−1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body.

摘要翻译： 通过使分散在8mg.mL-1或更高浓度的液体培养基中的蛋白质分子在零长度交联剂的存在下反应来制备蛋白质颗粒，以产生包含蛋白质分子的蛋白质颗粒， 共价键合。 蛋白质颗粒可以以亚微米范围内的尺寸制造，具有紧密限定的尺寸和尺寸分布。 这些颗粒在许多领域中具有应用，但是尤其可用于将治疗剂和其它试剂（例如成像造影剂）递送至身体。

公开(公告)号：US20150258218A1

公开(公告)日：2015-09-17

申请号：US14423946

申请日：2013-08-30

申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： Moritz Kircher ,  Stefan Harmsen ,  Matthew Wall

IPC分类号： A61K49/00 ,  A61K51/12

CPC分类号： A61K49/0093 ,  A61K49/00 ,  A61K49/0002 ,  A61K49/1878 ,  A61K49/1881 ,  A61K51/1251

摘要： The present disclosure, among other things, provides a composition including a nanoscale core; a plurality of capping agent entities associated on the core; an outer encapsulant layer; and a plurality of dopant entities distributed at locations selected from the group consisting of: on or within the nanoscale core, on or between capping agent entities, on or within the encapsulating layer, and combinations thereof. Provided technologies can achieve unprecedented levels of dopant entity density and/or surface localization, which, for a SE(R)RS-active agent dopant, results in dramatically improved signal intensity and/or imaging sensitivity.

摘要翻译： 本公开内容尤其提供了包括纳米尺度核心的组合物; 在核心上相关联的多个封盖代理实体; 外包封层; 以及分布在选自以下的位置处的多个掺杂剂实体以及其组合：在纳米级核心上或纳米级核心之上，覆盖剂实体之间或之上，在封装层上或封装层内。 所提供的技术可以实现前所未有的掺杂剂实体密度和/或表面定位水平，对于SE（R）RS-活性剂掺杂剂，其导致显着改善的信号强度和/或成像灵敏度。